Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Clin Pract Oncol. 2009 Jan;6(1):53-8. doi: 10.1038/ncponc1278. Epub 2008 Nov 18.

Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma.

Author information

1
Multimodality Molecular Imaging Lab, Department of Radiology & Bioengineering, Stanford University, Stanford, CA, USA.

Abstract

BACKGROUND:

A 57-year-old man had been diagnosed with grade IV glioblastoma multiforme and was enrolled in a trial of adoptive cellular immunotherapy. The trial involved infusion of ex vivo expanded autologous cytolytic CD8+ T cells (CTLs), genetically engineered to express the interleukin 13 zetakine gene (which encodes a receptor protein that targets these T cells to tumor cells) and the herpes simplex virus 1 thymidine kinase (HSV1 tk) suicide gene, and PET imaging reporter gene.

INVESTIGATIONS:

MRI, whole-body and brain PET scan with (18)F-radiolabelled 9-[4-fluoro-3-(hydroxymethyl)butyl]guanine ((18)F-FHBG) to detect CTLs that express HSV1 tk, and safety monitoring after injection of (18)F-FHBG.

DIAGNOSIS:

MRI detected grade III-IV glioblastoma multiforme plus two tumors recurrences that developed after resection of the initial tumor.

MANAGEMENT:

Surgical resection of primary glioblastoma tumor, enrollment in CTL therapy trial, reresection of glioma recurrences, infusion of approximately 1 x 10(9) CTLs into the site of tumor reresection, and (18)F-FHBG PET scan to detect infused CTLs.

PMID:
19015650
PMCID:
PMC3526373
DOI:
10.1038/ncponc1278
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center